-

The Law Offices of Frank R. Cruz Continues Its Investigation of Mercury Systems, Inc. (MRCY) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Mercury Systems, Inc. (“Mercury” or the “Company”) (NASDAQ: MRCY) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On July 26, 2022, Glasshouse Research published a report alleging that Mercury’s organic revenue is “overstated,” that its Physical Optics acquisition has been a “disaster,” and that management has prematurely recognized revenues.

On this news, Mercury’s stock fell $4.87, or 7.8%, to close at $57.26 per share on July 26, 2022, thereby injuring investors.

Then, on August 2, 2022, after the market closed, Mercury announced its fourth quarter and full year 2022 financial results, reporting $289.7 million in quarterly revenue, which is below prior guidance expecting revenue between $301.5 million and $321.5 million. The Company attributed the shortfall to “material and order delays that affected the timing of revenue.”

On this news, the Company’s stock fell as much as 13% during intraday trading on August 3, 2022, thereby injuring investors further.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Mercury securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

The Law Offices of Frank R. Cruz

NASDAQ:MRCY

Release Versions

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

More News From The Law Offices of Frank R. Cruz

Lost Money on Dave, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 21.25% Stock Decline

LOS ANGELES--(BUSINESS WIRE)--Dave, Inc. ("Dave" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Dave, Inc. (NASDAQ: DAVE), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Dave, Inc. on November 4, 2026.If you lost money on Dave, Inc. securities, share you...

Lost Money on MNTN, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 53.62% Stock Decline

LOS ANGELES--(BUSINESS WIRE)--MNTN, Inc. ("MNTN" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in MNTN, Inc. (NYSE: MNTN), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about MNTN, Inc. on November 4, 2026.If you lost money on MNTN, Inc. securities, share your...

Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 8.1% Stock Decline

LOS ANGELES--(BUSINESS WIRE)--Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Madrigal Pharmaceuticals, Inc. on Novem...
Back to Newsroom